Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network.
Clinical Trial Design and Development (CTDD)
Quantitative Imaging Network (QIN)
Journal
Tomography (Ann Arbor, Mich.)
ISSN: 2379-139X
Titre abrégé: Tomography
Pays: Switzerland
ID NLM: 101671170
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
25
6
2021
Statut:
ppublish
Résumé
The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.
Identifiants
pubmed: 32548281
doi: 10.18383/j.tom.2019.00022
pii: TOMO.2019.00022
pmc: PMC7289239
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-64Subventions
Organisme : NCI NIH HHS
ID : U01 CA225427
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227763
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA242879
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187947
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA140204
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA148131
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB004640
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132870
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA140207
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA140230
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA151235
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA232931
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179106
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA142555
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA190214
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA172027
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA140206
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Informations de copyright
© 2020 The Authors. Published by Grapho Publications, LLC.
Références
Tomography. 2016 Dec;2(4):276-282
pubmed: 28127586
J Nucl Med. 2017 Mar;58(3):393-398
pubmed: 27688473
J Clin Oncol. 2014 Jul 1;32(19):2115-6
pubmed: 24868025
Radiology. 2003 Jan;226(1):24-8
pubmed: 12511664
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235
pubmed: 29966725
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Clin Cancer Res. 2016 Jan 15;22(2):284-90
pubmed: 26773162
Tomography. 2019 Mar;5(1):A8
pubmed: 30854462
Magn Reson Imaging. 2012 Nov;30(9):1301-12
pubmed: 22898682
Radiology. 2015 Mar;274(3):781-9
pubmed: 25350641
Lancet. 2003 Jan 4;361(9351):71
pubmed: 12517476
BMJ. 2015 Oct 28;351:h5527
pubmed: 26511519
J Med Imaging (Bellingham). 2020 Jul;7(4):042803
pubmed: 32206688
Tomography. 2019 Mar;5(1):1-6
pubmed: 30854436
Radiology. 2015 Dec;277(3):826-32
pubmed: 26509226
Transl Oncol. 2014 Feb 01;7(1):1-4
pubmed: 24772201